Legend Biotech Corp. (LEGN) PT Lowered to $91 at Jefferies
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
Go back to Legend Biotech Corp. (LEGN) PT Lowered to $91 at Jefferies
January 22, 2025 11:11 AM EST
Goldman Sachs analyst Ziyi Chen reiterated a Buy rating and $84.28 price target on Legend Biotech Corp. (NASDAQ: LEGN).
The analyst comments "JNJ/Legend reported preliminary sales of US$335mn (+17% q/q, +111% y/y, vs. GSe of US$299mn, 4Q company-provided consensus... More
January 21, 2025 6:39 AM EST
H.C. Wainwright analyst Mitchell S. Kapoor reiterated a Buy rating and $73.00 price target on Legend Biotech Corp. (NASDAQ: LEGN).
The analyst commented: "Concerns remain of a world where Arcellxs (ACLX; Buy; Bodnar) ddBCMA and CARVYKTI coexist commercially, with persistent investor questions about the market share splits. Anito-cel has shown zero non-ICANS delayed neurotoxicity (including parkinsonism) in >150 patients to... More
